CoChat

Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential

Open access

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Polycystic ovary syndrome (PCOS) is associated with increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD) in later life. We aimed to study the effect of liraglutide intervention on markers of VTE and CVD risk, in PCOS. In a double-blind, placebo-controlled, randomized trial, 72 overweight and/or insulin-resistant women with PCOS were randomized, in a 2:1 ratio, to liraglutide or placebo 1.8 mg/day. Endpoints included between-group difference in change (baseline to follow-up) in plasminogen activator inhibitor-1 levels and in thrombin generation test parameters: endogenous thrombin potential, peak thrombin concentration, lag time and time to peak. Mean weight loss was 5.2 kg (95% CI 3.0–7.5 kg, P < 0.001) in the liraglutide group compared with placebo. We detected no effect on endogenous thrombin potential in either group. In the liraglutide group, peak thrombin concentration decreased by 16.71 nmol/L (95% CI 2.32–31.11, P < 0.05) and lag time and time to peak increased by 0.13 min (95% CI 0.01–0.25, P < 0.05) and 0.38 min (95% CI 0.09–0.68, P < 0.05), respectively, but there were no between-group differences. There was a trend toward 12% (95% CI 0–23, P = 0.05) decreased plasminogen activator inhibitor-1 in the liraglutide group, and there was a trend toward 16% (95% CI −4 to 32, P = 0.10) reduction, compared with placebo. In overweight women with PCOS, liraglutide intervention caused an approximate 5% weight loss. In addition, liraglutide affected thrombin generation, although not significantly differently from placebo. A concomitant trend toward improved fibrinolysis indicates a possible reduction of the baseline thrombogenic potential. The findings point toward beneficial effects of liraglutide on markers of VTE and CVD risk, which should be further pursued in larger studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/ec-16-0113

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow chart of included and excluded participants.
Figure 1 Flow chart of included and excluded participants.CC BY-NC · PubMed Central
Figure 2 Change in thrombin generation parameters after intervention with liraglutide or placebo for 26 weeks. Dots represent mean change from baseline to follow-up in the liraglutide group and squares represent mean change from baseline to follow-up in the placebo group. Data are presented as mean (95% CI). Within-group comparisons demonstrated decreased peak thrombin concentration (top right), increased time to peak (bottom left) and increased lag time (bottom right), *P < 0.05. NS, non-significant.
Figure 2 Change in thrombin generation parameters after intervention with liraglutide or placebo for 26 weeks. Dots represent mean change from baseline to follow-up in the liraglutide group and squares represent mean change from baseline to follow-up in the placebo group. Data are presented as mean (95% CI). Within-group comparisons demonstrated decreased peak thrombin concentration (top right), increased time to peak (bottom left) and increased lag time (bottom right), *P < 0.05. NS, non-significant.CC BY-NC · PubMed Central
Figure 3 Levels of PAI-1 at baseline and 26-week follow-up. Open circles represent the liraglutide group and black squares the placebo group. Data are presented as median (p25–p75) at baseline and follow-up. There was a trend toward decreased PAI-1 in the liraglutide group as compared with the placebo group, 16% (95% CI −4 to 32, P = 0.10). *P = 0.05. NS, non-significant; PAI-1, plasminogen activator inhibitor-1.
Figure 3 Levels of PAI-1 at baseline and 26-week follow-up. Open circles represent the liraglutide group and black squares the placebo group. Data are presented as median (p25–p75) at baseline and follow-up. There was a trend toward decreased PAI-1 in the liraglutide group as compared with the placebo group, 16% (95% CI −4 to 32, P = 0.10). *P = 0.05. NS, non-significant; PAI-1, plasminogen activator inhibitor-1.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 44

Metadata

Authors
Nylander, M., Frøssing, S., Kistorp, C., Faber, J., & Skouby, S. O.
Affiliations
University of Copenhagen (DK)
Corresponding author
Nylander, Malin
Venue
Endocrine Connections
Published
2017-02
Volume
6
Issue
2
Pages
89-99
ISSN
2049-3614 (ISSN-L)
OpenAlex
W2580304737
Cited by
44
References
48
Citations by year
2026: 10 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 1 · 2018: 5 · 2017: 3
FWCI
4.13
Type
journal article
Language
en
Open access
Locations
  • Endocrine Connections (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Gentofte Hospital
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
polycystic ovary syndrome, liraglutide, venous thromboembolism, cardiovascular risk, thrombogenic potential, thrombin generation, plasminogen activator inhibitor-1, fibrinolysis, weight loss, insulin resistance, overweight women, GLP-1 receptor agonists, endogenous thrombin potential, time delay

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.